Your shopping cart is currently empty

MR 409, a selective growth hormone-releasing hormone (GHRH) agonist, exhibits notable neuroprotective properties by augmenting endogenous neurogenesis in cerebral ischemic mice and demonstrates the ability to inhibit in vivo lung cancer growth [1] [2] [3] [4].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | MR 409, a selective growth hormone-releasing hormone (GHRH) agonist, exhibits notable neuroprotective properties by augmenting endogenous neurogenesis in cerebral ischemic mice and demonstrates the ability to inhibit in vivo lung cancer growth [1] [2] [3] [4]. |
| In vitro | One week after myocardial infarction (MI), MR 409 (MR-409) significantly diminishes plasma concentrations of IL-2, IL-6, IL-10, and TNF-α compared to placebo [1]. At a concentration of 1 μM, MR-409 attenuates p53 expression in bovine pulmonary arterial endothelial cells (BPAECs) and activates JAK2, STAT3, and ERK1/2 signaling pathways [2]. Furthermore, MR-409 (1 and 5 μM) reduces lipopolysaccharide (LPS)-induced PGE2 and 8-iso-PGF2α production in a dose-responsive manner, whereas it decreases LPS-induced lactate dehydrogenase (LDH) activity and nitrite levels independently of dose variation [3]. Similarly, gene expression of COX-2, NF-κB, and iNOS in colon specimens induced by LPS is mitigated by MR-409 at concentrations of 1 and 5 μM, again without showing dose-dependency [3]. Additionally, MR-409 stimulates endogenous neurogenesis and counteracts tMCAO-induced neuroplasticity deficits, along with promoting proliferation and reducing apoptosis in neural stem cells subjected to oxygen and glucose deprivation-reperfusion [4]. |
| In vivo | MR 409 (MR-409) suppresses lung cancer growth in vivo when xenografted into nude mice [3]. Additionally, when administered subcutaneously at a dose of 5 μg daily for four weeks, MR 409 diminishes the nociceptive response in mice [3]. |
| Molecular Weight | 3395.91 |
| Formula | C153H252N44O43 |
| Cas No. | 1445155-39-4 |
| Smiles | [C@@H](CC1=CC=CC=C1)(NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](NC([C@H](CC2=CC=C(O)C=C2)NC)=O)C)=O)CC(O)=O)=O)C)=O)[C@H](CC)C)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC3=CC=C(O)C=C3)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCCNC(=N)N)C(NC)=O)=O)CC(O)=O)=O)CCCC)=O)[C@H](CC)C)=O)CC(O)=O)=O)CCC(N)=O)=O)CC(C)C)=O)CC(C)C)=O)CCCN)=O)CCCNC(=N)N)=O)C)=O)CO)=O)CC(C)C)=O)CCC(N)=O)=O)CC)=O)CC(C)C)=O)[C@H](C)C)=O)CCCN)=O)CCCNC(=N)N)=O)=O)CO)=O)CC(N)=O)=O)[C@@H](C)O)=O |
| Sequence | {Asn-Me}-Tyr-{D-Ala}-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-{Orn}-Val-Leu-{Abu}-Gln-Leu-Ser-Ala-Arg-{Orn}-Leu-Leu-Gln-Asp-Ile-{Nle}-Asp-Arg-NHMe |
| Sequence Short | {N-Me}-Y-{D-Ala}-DAIFTNSYR-{Orn}-VL-{Abu}-QLSAR-{Orn}-LLQDI-{Nle}-DR-NHMe |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.